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Efforts to make vaccines against infectious diseases as well as immunotherapies for cancer, autoimmune
diseases and allergy have utilized a variety of heterologous expression systems, including viral and bacterial
vectors, as well as DNA and RNA constructs. This review explores the immunologic rationale and provides an
update of insights obtained from preclinical and clinical studies of such vaccines.Introduction
Traditional means of making vaccines against infectious disease
have been highly successful for a number of pathogens with a
resultant decrease in their rates of infection. However, the usual
approaches have had limitations for certain diseases such as
HIV and for diseases either not due to infections, or in which
the appropriate target antigen is unclear, such as for certain
cancers and autoimmune diseases. Challenges for making
such vaccines include knowing the type of immunity that is
needed or thought to be needed for particular pathogens or
diseases, as well as unique biological and pathophysiological
characteristics of a given pathogen or disease process. For
example, attenuated virus vaccines are extremely effective,
and they are perhaps the best way to stimulate all the compo-
nents of immunity (including at least some degree of memory)
that infection with the pathogenic organism does, without the
obvious morbidity and mortality of wild-type infection. But not
only are some pathogens considered perhaps too risky even in
attenuated form, but also the immune responses elicited by
wild-type infection are not necessarily effective for clearing
a pathogen after an infection. Infection with HIV is an obvious
example in which infection does not induce effective immunity,
and hence the immune responses that occur after HIV infection
may not be goodpredictors of the type of immunity that a vaccine
should generate. Inactivated pathogen or subunit vaccines, such
as for influenza, are generally used for pathogens for which
a humoral immune response is considered the primary protec-
tive immune response and as such would be inadequate for
inducing the appropriate forms of cellular immunity needed for
certain diseases. Therefore new technologies have been devel-
oped and explored for making vaccines that elicit the forms of
immunity thought to be most important for a given infectious
agent or disease. Inducing primarily antibodies or cytolytic
T cells or modifying the type of T cell help, such as for preventing
or treating autoimmune or allergic diseases, might be best
accomplished by different vaccine technologies that deliver the
antigen in such a way as to induce a particular arm of immunity
or to bias the type of immune response. Vectors are delivery
systems often derived from pathogens and are used to deliver
genes encoding antigens of a different pathogen. In other words,
a modified bacterium, virus, plasmid, or gene sequence derived
from a pathogen that is used to deliver a gene encoding an
antigen is a vector that when given to a vaccinee results in the
in situ production of the antigen. This distinguishes it from a504 Immunity 33, October 29, 2010 ª2010 Elsevier Inc.traditional vaccine that involves the direct administration of the
pathogen or some part of the pathogen (versus a gene encoding
it) against which the immune response is desired. This review will
explain the rationale for different types of vectors, then compare
vectors under development. Vectors for vaccine delivery include
plasmid DNA, RNA, viral vectors, and bacteria. Some of the
attributes are shown in Table 1.
Immunologic Rationale for Vaccine Vectors
New vaccine modalities have been explored that could generate
the appropriate forms (and duration) of immune responses while
simultaneously focusing the immune response on the desired
antigen (Nabel et al., 2010). For viral infections and cancer, for
example, cellular responses, such as cytolytic T cells (CTLs),
are thought to be an important part of the immune responses,
and in addition to targeting the virally infected cells (versus
the virus itself) or the tumor cells directly, they can target
epitopes that are conserved between different strains of a virus
or between different tumors, which often are internal or func-
tional proteins, and hence are less accessible to antibodies.
Thus efforts have been made to generate vaccines (and
immunotherapies) that can generate CTL responses. This is
one of the main rationales for developing vectored vaccines
because they are able to deliver heterologous antigens into the
antigen-processing pathways needed to stimulate MHC class
I-restricted CTL responses (Liu, 2010). The intent is to generate
an immune response against epitopes from proteins that are
more highly conserved between viral strains or tumor antigens
that are common to a particular type of tumor in order to make
a vaccine that is broadly protective or useful against tumors
arising in different individuals. These approaches are not meant
to imply that the humoral response is not an important compo-
nent of vectored vaccines, but rather they are a way to generate
a cellular response that heretofore had been difficult to stimulate
without using a live attenuated vaccine. Vector vaccines can also
result in antibodies (as well as the cellular responses) directed
against the encoded antigen.
Although it is possible to directly introduce proteins into the
MHC class I processing pathway, such as through the use of
certain particles (Oh et al., 1997) including hepatitis B surface
antigen particles (Schirmbeck et al., 1998), it is more universally
feasible to deliver a gene encoding the antigen into cells from
which the relevant peptide epitopes could ultimately be appro-
priately presented on the MHC class I molecules (Donnelly
Table 1. Examples of Vaccine Vectors
Vector Potential Advantages Issues/Concerns
Nucleic Acids
Plasmid DNA Licensed veterinary vaccines Low human potency without heterologous boost
Relatively generic construction and production Use of delivery device or technology will increase
complexity and cost
Potent prime in animal studies
RNA Considered to have fewer safety regulatory issues than
other vectors, e.g., no integration, no issue of
autoimmunity
Instability; likely require formulation and/or delivery
technology
Facile production with high purity
Viruses
Poxviruses Licensed veterinary vaccine vector Possible issue of pre-existing immunity for vaccinia
(smallpox) vaccinees
MVA known clinical safety Probably will need prime, increasing complexity and cost
Room for large gene insert
Various strains available
Adenovirus Historic oral adenovirus vaccine Pre-existing immunity to certain human strains may not
preclude use as vectors, but results of HIV STEP trial need
to be understood re: safety for high-titered vaccinees
relative to subsequent risk of HIV infection if exposed
Strong immune responses Human Ad strains oncogenic in animals
Many strains available
Adeno-associated virus Apparent efficacy as vector in small gene
therapy trial for eye diseasea
Disputed risk of integration
Safety shown in small gene-Rx trials Limited gene insert capacity
Alphaviruses Virus particles or DNA replicons Modest gene capacity
High expression
No risk of integration because RNA particle
can target DCs
Herpes virus Broad tropism including DCs Neurotropism may be safety issue
Possible pre-existing immunity
Measles virus Mucosal delivery possible Possible pre-existing immunity
RNA virus (no integration issue)
Vesicular stomatitis virus Broad tropism including DCs Neurotropismb may be safety issue
High expression
Bacteria
Salmonella/Shigella Oral delivery Concern about heterologous gene if on plasmid
Infect M cells (gut antigen uptake cells) Potential stability of antigen gene if on plasmid
BCG Extensive safety of BCG vaccine Bacterial (versus mammalian) posttranslational
modifications
Listeria Efficient mechanisms for CTL induction Concerns re: vector virulence in immunocompromised
aMaguire et al., 2008.
b Johnson et al., 2007.
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this, including direct cell transfection, and the use of vectors,
initially viral vectors, but also bacteria and plasmid DNA (Liu,
2010).
Other developments that increased the interest in vectored
vaccines included the focus on particular antigens or even
epitopes. Early vaccines were based on whole organisms (e.g.,
vaccinia, BCG), but attention moved to key proteins, such as
the toxins of diphtheria and tetanus, or the surface antigen of
hepatitis B. The rationale was that those molecules were essen-tial targets for antibody responses. Subsequently, a new
strategy for targeting different proteins was developed for those
proteins that are not necessarily accessible to antibodies, but
rather that are more conserved between viral strains due to their
function and/or location (Rolland et al., 2007). For example, early
studies of the genetics of HIV strains revealed that Gag and Pol
proteins are more highly conserved than Env (Peeters et al.,
1991) (Alizon and Montagnier, 1987), and Env contains highly
variable regions (Gao et al., 1996), which rapidly mutate in
response to antibody responses. Similarly, influenza subtypes,Immunity 33, October 29, 2010 ª2010 Elsevier Inc. 505
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et al., 2002) and neuraminidase surface proteins, which mutate
frequently (Xu et al., 1996), readily escape antibody-based viral
neutralization by minor mutations in these proteins necessitating
the annual reformulation of the influenza vaccines (Doherty et al.,
2006). Yet they have much less variability in their nucleoproteins,
even between influenza viruses of different subtypes and
between such epidemic strains separated by many years
(Thomas et al., 2006).
A study in humans demonstrated that CTLs have cross-reac-
tivity with another strain of influenza. In that study, people were
intentionally infected with a strain of influenza, and those who
had CTLs cleared infection whether or not they had pre-existing
antibody directed against the virus, and their CTLs were found to
be able to kill cells infected with the challenge virus even if they
had no evidence of previous infection with the challenge virus,
i.e., their CTLs were able to cross-react with a new subtype of
virus. (McMichael et al., 1983). As the HIV-AIDS epidemic
develops, the cellular immune responses, notably CD4+ T cell
help (Day and Walker, 2003), and CD8+ CTL responses (Harrer
et al., 1996; Goulder et al., 1996) were found to play a role in viral
containment (Rowland-Jones et al., 1999). Humanmemory CTLs
have also been found to be effective against different strains of
virus (Gianfrani et al., 2000). Certain of these cellular responses
were directed against epitopes that were conserved between
different strains (Johnson et al., 1991). This led to two aspects
for the development and use of vectors: the first being to find
means to deliver antigens in a way as to generate both CTL
and appropriate T helper cell responses, and to be able to deliver
just the key antigens desired, which could easily be accom-
plished by the use of vectors rather than attenuated organisms.
The utilization of only certain proteins or even epitopes to focus
the immune response on critical (e.g., neutralizing) (Muster et al.,
1994) or conserved regions (Hammond et al., 1991) (Nishino
et al., 1994) (Johnson et al., 1994) is an effort to ensure that the
immune response would be effective for controlling viremia
and would be effective against a broad array of viral strains
(Kuwano et al., 1989; Ulmer et al., 1993). Another rationale for
limiting the proteins delivered, or excluding portions of proteins,
was to eliminate proteins with deleterious functions (such as the
transforming capabilities of human papilloma virus E6 [Sedman
et al., 1991]). Thus, vectors could be used to deliver the genes
encoding only the specific antigens against which an immune
response is desired and can deliver the gene or antigen such
that the desired immune responses are generated.
Different vectors and delivery modes were found to stimulate
or bias different T helper responses. The type of T cell help is
thought to not only affect the type of immune response (e.g.,
antibodies versus CTLs) but to potentially play a role in limiting
disease progression (e.g., in HIV [Rosenberg and Walker,
1998]). Thus, there are increased efforts to develop specific
vectors not only to generate specific CTLs and/or antibody
responses but also to promote the type of T cell help (i.e., T
helper 1 [Th1] or Th2) for diverse applications, such as for
prevention of infectious diseases or asthma and diabetes,
respectively (Liu, 2010).
Efforts to develop vectors have taken into account a variety
of other factors such as the ease of manipulation of the vectors,
gene capacity, expression of the heterologous protein, produc-506 Immunity 33, October 29, 2010 ª2010 Elsevier Inc.tion of the vectors, and safety. One aspect that was little under-
stood in the early days, and that is still too complicated to fully
factor in, is the immune response against the vector itself. This
includes issues related to reuse of a vector, or the use of vector
in persons who have been previously exposed to the virus or a
related virus, such as for smallpox vectors in previously
immunized individuals. Additionally, stimulation of innate immu-
nity by the vectors themselves (Ulmer et al., 2006; Zhu et al.,
2007) is considered an attribute that can increase the potency
of vectored vaccines, although clearly the interactions between
the innate and adaptive immune systems are poorly understood.
The final aspect of the rationale for utilizing vectors to deliver
vaccines is the targeting of delivery, not just to the antigen-pro-
cessing pathways but to particular cells or subsets of cells.
Although adenovectors target a broad range of cells, this in
some ways may be a limitation of their utility because of the
efficiency with which they bind to nonantigen presenting cells
(non-APCs), such as liver cells (Arnberg, 2009). Efforts to specifi-
cally direct vectors to or away from certain cell types have
included the addition or deletion of targetingmotifs on the vectors
(Einfeldetal., 2001) and formulationofDNAplasmids inoronparti-
cles to enhance their uptake by APCs (Denis-Mize et al., 2000).
Throughout this discussion, it must be remembered that
although vaccine research and development has targeted
particular immune responses, and particular antigens, we have
a relatively incomplete understanding of all of the components
of the immune response that comprise a protective response,
even for licensed vaccines. That is, except for certain vaccines,
a particular antibody titer is generally used as the correlate of
protection. For other vaccines we do not have an antibody titer,
nor a measure of cellular responses that can be considered
protective, particularly when the cellular immunity is thought to
be crucial. Moreover, our usual source of sampling for immune
responses, especially in large-scale efficacy studies, is periph-
eral blood, which gives us a very incomplete picture of the
protective immune responses at the initial sites of infection
(mucosal surfaces) or target organs. Measurement of single
types of immune responses gives a limited understanding of
the composite and interactive nature of the various responses.
Thus this discussion of the immune responses, and comparisons
between different vectors, is akin to the proverbial description of
an elephant by six blind men, in which the measured immune
responses only reveal a portion of the complex immune
response. It must also be remembered that although this review
will focus on the immune responses of the vectored vaccines,
any particular vaccine can be made and will be utilized on the
basis of the sum of its attributes, which include not only
immune responses (which may vary in different populations),
but foremost safety, as well as ease and cost of manufacture,
distribution, and administration.
Viral Vectors
Various viral vectors have been developed and reached clinical
trials. Interestingly, several of these were also the basis for gene
therapy efforts when an immune response against the gene
product would not be desired. The intrinsic characteristics of the
vectors lead to specialized applications or determine their
potency as vaccine vectors. For example, herpes virus vectors
are under development not only as vaccine vectors but also as
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encoding therapeutic agents to the CNS because of their tropism
for the nervous system (Manservigi et al., 2010). Vesicular stoma-
titis virus (VSV) has been shown to target DCs, perhaps account-
ing for the potent immune responses seen when it is used as a
vector (Boudreauet al., 2009). The vectors that have themostdata
from clinical trials include adenovectors and pox vectors, includ-
ing both canary pox and modified vaccinia ankara (MVA). The
measured immune responses for vaccines and immunotherapy
focuson: (1) immune responsesdirectedagainst the heterologous
antigen, (2) the adaptive immune responses directed against the
vector, and how these affect the use and reuse of the vector,
and (3) the innate responses against the vector, and the impact
upon the antigen-specific immune responses.
The immunological rationale for selecting a particular viral
vector includes how well the heterologous gene is expressed
because the quantity of antigen may affect the extent of the
immune response. In addition, the type of cells that produce
the antigen following transfection by the virus vector, may affect
the nature and potency of the immune response. Another factor
influencing the choice of vector is the persistence of the virus
(e.g., herpes [Liu et al., 2009]), whichmight be useful for prolong-
ing immunity. Because so many of the factors governing the
induction of optimal immunity are incompletely understood
(such as the activation of the innate immune system by various
components of vectors and the effect upon the adaptive immu-
nity), it is hard to know exactly what would make the best vector
for any given vaccine. Given the expensive and long develop-
ment process required for clinical testing, the choice of one
vector over another for the vaccines described below has been
largely based upon key characteristics of a vector and extensive
preclinical studies for that vector rather than exhaustive head-to-
head comparisons of vectors and administration protocols,
since regimens, doses, and matrices of prime-boost combina-
tions could lead to innumerable variables.
Pox Virus Vector
Pox viruses are selected as potential vectors for several reasons:
the extensive use of the smallpox vaccine (and the related
modified vaccinia ankara), which provided knowledge of the
human safety parameters; the large gene capacity for the inser-
tion of a heterologous gene encoding the antigen of interest; the
broad tropism of the virus for mammalian cells that could then
result in a number of cells expressing the heterologous antigen;
the production of antigen for a relatively short period of time
(making the kinetics of the production of the heterologous
protein more akin to antigen production from an acutely infecting
pathogen, but less useful for gene therapy applications); and the
location of the virus in the cytoplasm, thus avoiding integration
risks that might occur with a retroviral vector, for example
(Mastrangelo et al., 2000). The earliest vector for delivery of a
heterologous antigen is a licensed veterinary vaccine employing
a modified vaccinia ankara vector to deliver a rabies antigen
(Mackowiak et al., 1999). The vaccine was developed in order
to be delivered as bait for wild animals. The vector not only
expressed the heterologous antigen, but as a smallpox vaccine
had been tested in 150,000 humans including immunocompro-
mised individuals (McCurdy et al., 2004). The success of using
a vector to deliver an antigen that generated immunity sufficient
to protect animals and curtail outbreaks in the wild, via oraldelivery of bait (hence with imprecise dosing), in a variety of
animal species, demonstrates many of the advantages of an
ideal vectors, in this case efficacy, safety, and even ease of
distribution (oral delivery), which would not have been as facile
with a nonvectored vaccine.
Various pox vectors have undergone human clinical testing as
HIV vaccines (Hanke et al., 2002a; Hanke et al., 2002b; Peters
et al., 2007;Vasanet al., 2010;Weeet al., 2002). In the largest clin-
ical trial, a canary pox vector coding for HIV antigens was utilized
as the first component of a prime-boost regimen (see below) in
a clinical trial of an HIV vaccine involving 16,000 individuals
(Rerks-Ngarm et al., 2009). This study utilized a recombinant
protein boost and demonstrated modest protective efficacy. In
another heterologous prime-boost vaccination protocol for
prophylaxis of HIV, the priming is being donewith aDNAplasmid,
followed by an MVA vector boost (http://clinicaltrials.gov/ct2/
show/NCT00820846?term=DNA+%2B+MVA+for+HIV&rank=5).
Adenovirus Vector
The STEP trial was a proof-of-concept human clinical trial for
prevention of infection with HIV and utilized an adenovirus vector
encoding HIV proteins (Buchbinder et al., 2008; McElrath et al.,
2008). Because of the concern that pre-existing adenovirus
(Ad5) antibodies would make such a vaccine less effective, by
binding to the vaccine and diminishing its activity, the study
was done both in individuals with high and low titers of pre-exist-
ing adenovirus antibody. The human trial was stopped when it
was clear that it would not be possible to demonstrate that the
vaccine had efficacy (so called ‘‘futility’’ of the trial) (Buchbinder
et al., 2008). However, one result that came out of the study was
that more individuals who had high titers of adenovirus anti-
bodies before being immunized became HIV infected than did
similar patients who received the placebo. No differences in
rates of HIV infection were seen in patients receiving vaccine
or placebo in individuals who had low pre-existing adenovirus
antibody titers.
One possible explanation for these results, aside from it being
stochastic, is that in patients with high anti-Ad5 titers, (i.e.,
presumably indicative of prior infection with adenovirus 5, and
hence also with pre-existing Ad5 T helper cell responses) acti-
vated Ad5-specific T cells were more susceptible to infection
by HIV. Two subsequent studies seemed to indicate that this
mechanism was not responsible, by their demonstration of a
lack of correlation between the titer of Ad5 antibodies and the
frequency of Ad5-specific T cells either before or after immuniza-
tion (Hutnick et al., 2009; O’Brien et al., 2009). However, a further
study showed that when T cells from individuals who had pre-ex-
isting antibodies against adenovirus were stimulated with
adenovirus, an increase in memory CD4+ T cells occurred, and
these T cells were more easily infected with HIV (Benlahrech
et al., 2009). In addition, these T cells homed to mucosa, which
could provide an explanation for the results of the two prior
studies that had sampled peripheral blood lymphocytes rather
than mucosal lymphocytes (Benlahrech et al., 2009). These
studies highlighted, among other issues, that many of the read-
outs of immunologic parameters have utilized peripheral blood
lymphocytes, which may not reflect cells or immune conditions
in organs or at the sites of infection.
As noted above, another concern about using vectors is the
pre-existing immunity either from natural infection or from priorImmunity 33, October 29, 2010 ª2010 Elsevier Inc. 507
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evaluating the effect of prior immunization with an adenovector
not encoding an HIV gene, which was included in the vector
used for the second injection, the immune response against
the HIV antigen was diminished but not eliminated compared
to adenovirus vector-naive monkeys (Casimiro et al., 2003).
For humans, pre-existing immunity would include both prior
infection with wild-type Ad5 and prior use of Ad5 as a vector
(Quirk et al., 2008), (Harro et al., 2009). However, this may not
be an issue for all vectors. In a clinical trial employing an MVA
vector encoding several HIV genes, older individuals, who by
dint of their age had been previously immunized against
smallpox (a practice discontinued in 1980 after smallpox was
declared eradicated in 1977) did indeed have lower immune
responses than people not previously immunized for smallpox
(Gudmundsdotter et al., 2009). But it is possible that the lower
immune responses were due to the fact that the former group
was older, because cellular immunity, in particular, is known to
diminish with age.
The desire to increase the ability to reuse adenovectors
has led to efforts to develop Ad5 constructs lacking various
adenovirus genes (in addition to the genes already removed to
make the vectors incapable of replication) to eliminate the immu-
nogenicity of the expressed proteins (Gabitzsch et al., 2009),
(Weaver et al., 2009), (Koup et al., 2009). Other groups have
turned to adenoviruses that do not normally infect humans
such as those derived from chimpanzees (Rodrı´guez et al.,
2009), (Santra et al., 2009), (Tatsis et al., 2009). In addition,
approaches are being evaluated for decreasing immune
responses against the vector (Thacker et al., 2009). Nonreplicat-
ing adenovectors have been the primary focus of vaccine
development because of concerns related to use of replica-
tion-competent adenovirus in immunodeficient individuals and
concerns about the animal oncogenicity of human adenovirus
strains. But replicating adenovectors yield more potent cellular
and antibody responses against heterologous antigens (Rob-
ert-Guroff, 2007) and could be administered orally (Go´mez-
Roma´n et al., 2006). Thus replicating adenovectors for use as
an HIV vaccine are under development, and have been explored
as primes for heterologous prime-boost regimens (Patterson
and Robert-Guroff, 2008), more fully discussed below.
Bacteria Vector
Several attributes of bacteria led to their development as vaccine
vectors. These included the ability to deliver them via the oral
route,which is thenatural routeof infection for a varietyofbacteria
such as Salmonella (Fouts et al., 1995a; Fouts et al., 1995b),
(Chin’ombe et al., 2009), (Huang et al., 2009), Shigella (Fennelly
et al., 1999), and certain Mycobacteria such as M. bovis (Ferrari
et al., 2000). Of note, attenuated bacteria are used. The heterolo-
gous (i.e., vaccine) antigen could either be made as a bacterial
protein, or the bacteria could be used to deliver a plasmid encod-
ing the antigen under control of a viral promoter for protein
production by the infected mammalian host cell. The immuno-
logic rationale for bacterial vectors has therefore also been that
intracellular bacteria, could deliver the antigen or the plasmid
into cells for intracellular production of the antigen, with subse-
quent introduction of the antigen into theMHC class I processing
pathway. Thus both humoral and cellular immune responses can
be generated. Interestingly, in a study of Salmonella vectors used508 Immunity 33, October 29, 2010 ª2010 Elsevier Inc.to deliver plasmid encoding antigen, it was determined that
prokaryotic production of the antigenwasnecessary for immuno-
genicity rather than simply the mammalian production in the host
cell (Gahan et al., 2009). A potential issue for bacterial vaccine
vectors given orally, is the concern that the heterologous gene,
if present on a plasmid, could be transferred to other bacteria
(Zhang et al., 2008). In addition, for bacterial delivery of plasmid
DNA vaccines, high copy plasmid numbers are generally used,
and these may be unstable (Huang et al., 2010).
DNA and RNA Vectors
DNA, RNA and oligonucleotides have been directly delivered into
cells in vitro as ameans to have recombinant proteins expressed
in situ, or to affect the synthesis of endogenously encoded
proteins (such as with the delivery of siRNA). Because intracel-
lular bacteria and viruses have specific structures and mecha-
nisms for their infection of cells, the direct transfection of cells
by DNA or RNA was considered too inefficient to transfect
cells in vivo, particularly given the degradability of the genetic
material. So the demonstration that plasmid DNA could directly
transfect muscle cells when injected directly in vivo, and that
the encoded gene could be expressed (Wolff et al., 1990) was
unexpected. Moreover, because DNA plasmids when injected
are primarily taken up by, and expressed in, muscle cells (Wolff
et al., 1990), the observation that immune responses could be
generated against the encoded protein, including MHC class
I-restricted CTLs that could protect against infectious challenge
with a heterosubtypic virus (Ulmer et al., 1993), was even more
surprising. The immunologic mechanism was only understood
when it was shown that cross-priming could occur, whereby
antigen produced in non-APCs could be somehow transferred
in a way to professional APCs (Fu et al., 1997), and that a low
number of APCs could also be directly transfected (Ulmer and
Otten, 2000).
Another mechanism for the immune responses against
proteins encoded by DNA vaccines is the innate responses
directed against the plasmid itself. Studies demonstrated that
addition of noncoding plasmid to plasmid coding for antigen
resulted in greater immune responses (Donnelly et al., 1995),
(Sato et al., 1996). Because the plasmid is bacterial in origin,
its sequences contain CpG motifs that stimulate Toll-like
receptor 9 (TLR9) (Klinman et al., 1997), (Hemmi et al., 2000)
with a resultant augmentation of the cognate immune response
against the antigen encoded by the plasmid. However studies
in Tlr9 +/+ and Tlr9 / mice yield different conclusions. Tudor
and colleagues demonstrate that TLR9 signaling is not needed
for generation of the cognate immunity, but did appear to
augment the immunity against the antigen encoded by the
DNA (Tudor et al., 2005), whereas Babiuk and colleagues
demonstrate that both types of mice generated similar immune
responses (Babiuk et al., 2004), and Spies and colleagues
showed that although DNA vaccines activate DCs via TLR9
they could activate responses in TLR9-deficient mice (Spies
et al., 2003). Efforts to increase the potency of DNA plasmid
vaccines by the addition of immunostimulatory CpG sequences
have met with limited success, although synthetic CpG oligonu-
cleotides do increase the potency of protein antigens. A recent
study has provided a possible explanation for the different
outcomes of the above studies, by demonstrating that the role
of the CpGmotifs in activating DCs may be important for a prime
Box 1. Mechanisms to Increase the Potency of DNA and RNA
Vaccines
Figure 1. Induction of Immune Responses after Transfection of
Plasmid DNA Encoding an Alpha Virus Replicon versus Simple
Plasmid DNA
The replicon DNA encodes both the heterologous antigen and the alpha virus
proteins needed to replicate the genetic material but not the alpha virus struc-
tural proteins. Thus, the RNA is self-replicating and results in the production of
larger amounts of heterologous antigen than from a usual DNA plasmid driven
by a typical CMV promoter. Innate responses are also stimulated by the alpha
virus proteins and double-stranded RNA alongwith apoptosis. The net effect is
a highly potent immune response against the encoded heterologous antigen.
Proposed mechanisms are shown by dashed lines, with solid lines denoting
proven pathways.
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regimen (Rottembourg et al., 2010).
Other oligonucleotides that may prove useful include linear
DNA, which can be produced enzymatically in cell-free systems
(Vilalta et al., 2007). RNA has also been studied for vaccines and
immunotherapy of cancer (Pascolo, 2006), as well as for immu-
notherapy of allergy (Weiss et al., 2010) but the increased
susceptibility to degradation of RNA compared to DNA has
required additional stabilizing technologies (Kuhn et al., 2010).
Clinical trials have been performed for patients with melanoma
utilizing mRNA coding for melanoma antigens or using mRNA
derived by extracting total RNA from a resected melanoma
metastasis to make cDNA libraries which could then be tran-
scribed to produce mRNA for immunotherapy (Weide et al.,
2008; Weide et al., 2009). RNA has long been known to activate
the innate immune system, and mRNA condensed on protamine
in order to render it less susceptible to degradation has been
shown to stimulate DCs via TLR-7 and TLR-8 (Scheel et al.,
2005).
Additionally, DNA or RNA encoding alphavirus replicons are
under development and evaluation. Replicons encode not
simply the antigen, but by encoding viral enzymes of an alpha
virus, generate self-amplifying RNA. Both DNA and RNA repli-
cons have been made and have been based on several alpha
viruses (Liu et al., 2006). They result in production of high
amounts of antigen, although for a short period of time (Karlsson
and Liljestro¨m, 2004), as well as stimulating innate (anti-viral)
responses directed against the dsRNA (Leitner et al., 2003)
and apoptosis (Leitner et al., 2004) (see Figure 1) with the net
effect to be increased immunogenicity compared to when
comparable doses of regular plasmid DNA are used. However,the size of replicon DNA plasmids may limit their ability to trans-
fect cells in vivo, because they are several-fold larger than the
typical DNA plasmids. Indeed a primate study comparing DNA
replicons with regular plasmid DNA demonstrated similar
immune responses (Otten et al., 2004), although a another study
demonstrated that a chimeric replicon could protect both juve-
nile and infant macaques from measles (Pan et al., 2010).
Although efforts to increase the potency of viral vectors have
centered on issues specific for the virus, such as pre-existing
immunity, and increasing or decreasing the innate and virus-
specific immune responses, the approaches for DNA vaccines
can be described as ways to build back in those attributes of
a pathogen that enhance immunity, but in more surgical way
than might be possible by starting with a pathogen as a vector
(Box 1). These efforts fall into two main categories: improved
formulation and delivery to the relevant immune system, and
the provision of additional immunologic help in the form of
adjuvants and cytokines, whether via the innate or adaptive
immune systems. DNA formulation and delivery encompass
a broad array of approaches meant to stabilize the DNA, enable
it to be delivered more facilely, (e.g., orally), result in higher
antigen expression (Wang et al., 2006), and to deliver the DNA
to APCs (or increase cross-priming) or specifically augment the
immune response against the cognate antigen. Of course
some of the technologies have multiple effects, such as a
cationic lipid formulation designed to protect the DNA which
also has adjuvant activity (Hartikka et al., 2009) (Sedegah et al.,
2010). These concepts have been recently reviewed elsewhere
(Nabel et al., 2010).
Because particles (1–10 microns diameter) are taken up by
APCs, one approach has been to formulate DNA into or onto
microparticles, which should serve to protect the DNA as well
as to direct it to APCs rather than to either muscle cells orImmunity 33, October 29, 2010 ª2010 Elsevier Inc. 509
Immunity
Reviewdegradation (Xiang et al., 2010), (DeLong et al., 2009), (Denis-
Mize et al., 2003). DNA coated onto gold beads has also been
delivered via propulsion into the skin. In this case, the DNA is
directed into any cell in its pathway, including Langerhans cells.
This direct transfection of APCs may be responsible for the
potency of such ‘‘gene-gun’’ delivered DNA compared to intra-
muscularly injected plasmid. In clinical trials performed in indi-
viduals who had not responded to the licensed recombinant
protein vaccine, injection of gold beads coated with a DNA
vaccine resulted in the production of antibodies (Rottinghaus
et al., 2003). However, the dose of DNA that can be delivered
per ‘‘shot’’ means that multiple injections into multiple sites are
required, limiting the attractiveness of the technology. Another
device, the Biojector, shoots the liquid-formulated plasmid
into the skin, in an effort to also directly transfect Langerhans
cells (Rao et al., 2006), (Bra˚ve et al., 2005). In vivo electroporation
enables a substantial increase in uptake of DNA into cells,
with a resultant increase in protein production and immunoge-
nicity (Chiarella et al., 2010). The safety (in terms of risk of
integration) and clinical applicability of this technology is under
evaluation.
During the years following the development of the recombi-
nant Hepatitis B vaccine, vaccine efforts focused on the devel-
opment of ‘‘surgical’’ types of vaccines that depended on single
antigens, or even limited epitopes, to generate protection. How-
ever, it became clear that for most vaccines, even though a
particular antibodymight be critical in terms of being responsible
for the neutralization of the virus, or the lysis of a bacteria, that
a variety of immunologic cells and factors played key roles in
generating the response that received credit for the protection.
A DNA vaccine lends itself to being able to specifically add
back in those elements of the immune system to either augment
a response, or tomodify the response toward the desired pheno-
type. This could easily be accomplished by co-administration
of cytokines or chemokines or their genes (as DNA plasmids)
(Barouch, 2006), (Stevenson, 2004). Efforts to harness the innate
immune system have been discussed above for both plasmids
and viral vectors.
Additional immunologicmanipulations have included efforts to
cause apoptosis of the cell expressing the antigen (Parsania
et al., 2010) (Bergmann-Leitner et al., 2009) to increase cross-
priming, and hence to augment the immune response. However,
in other systems, an anti-apoptosis gene increases the immuno-
genicity (Dharmapuri et al., 2009) (Kim et al., 2004). In one case,
the beneficial effect of the anti-apoptosis gene appears to be
due to inhibition of gp140-mediated cytolosis, resulting in higher
amounts of expression of gp140 (the antigen) (Su et al., 2008).
Another explanation may be that different degrees of apoptosis
determine the immunological outcome (Kojima et al., 2007). It
may be that the effect is dependent upon whether the antigen
expression occurs in professional APCs (in which case, pro-
longed expression of the antigen would yield a greater immune
response), versus in non-APCs, wherein apoptosis would
enhance the cross-priming (Chattergoon et al., 2000).
Prime-Boost Immunization
Perhaps themost interesting, and immunologically poorly under-
stood approach to increasing the potency of vectored vaccines
has been the use of a mixed-modality vaccine wherein a prime510 Immunity 33, October 29, 2010 ª2010 Elsevier Inc.(or series of priming immunizations) is given with one type of
vaccine, such as a DNA vaccine, followed by a boost (or series
of boosts) with another type of vaccine, such as a viral vector,
or a recombinant protein. The concept of heterologous prime-
boosting arose when an initial immunization with plasmid DNA
followed by a viral vector, both encoding the same antigen, was
more potent for generating immune responses than either the
DNA or viral vector alone or given in the opposite order, and
provided better protective immunity to malarial challenge
(Schneider et al., 1998). Preclinical and clinical trials of combina-
tions of various modalities (DNA vaccines, viral vectors, bacterial
vectors, recombinant proteins) have been performed (Nabel
et al., 2010), with the most extensive being the 16,000 patient
trial for an HIV vaccine described above, consisting of a pox
vector followed by a recombinant protein boost (Rerks-
Ngarm et al., 2009). Additional HIV vaccine trials include a
Phase II study utilizing plasmid DNA then a boost with an Adeno-
vector5 (http://clinicaltrials.gov/ct2/show/NCT00865566?term=
DNA+ad5+HIV+phase+II&rank=1, or ClinicalTrials.gov Identifier
NCT00865566), a Phase I study using a DNA plasmid prime
boosted with either an Ad 35 or an Ad5 vector (http://
clinicaltrials.gov/ct2/results?term=NCT+00801697, or Clinical
Trials.gov Identifier NCT 00801697), and a phase II study
utilizing adenovectors delivered by either needle or Biojector
(http://clinicaltrials.gov/ct2/show/NCT00709605?term=Biojector&
rank=3; identifier NCT 00709605).
The immunologic explanation for the increased immune
responses in prime boost protocols and the reason that the
sequence of priming with DNA plasmid followed by another
modality, whether recombinant protein or viral vector, is neces-
sary are not well understood. However, the lack of additional viral
antigens (of the vector) when DNA is the prime, may help focus
the immune response on the key antigen (de Mare et al., 2008).
The additional innate antiviral responses, and cytokine milieu
that develop following the viral vector boost, may augment the
booster response. Recombinant protein has been utilized as
a boost to increase the antibody responses, as DNA vaccines
have often been considered better at inducing CTLs than anti-
bodies in higher species (Liu, 2010).
Vectored Vaccines for Veterinary Applications
Several vector-based vaccines have been licensed for animal
applications including the MVA-vectored rabies vaccine
described above and several DNA vaccines. The DNA vaccines
span the range of a fish vaccine against infectious hematopoietic
necrosis virus (IHNV) for use in salmon (Kurath, 2005) to a mela-
noma immunotherapeutic vaccine for dogs (Bergman et al.,
2003), and an equine vaccine against West Nile virus (Turell
et al., 2003). The relatively easy success of generating immune
responses and protection against disease in a host of preclinical
models, followed by either poor immunogenicity, or good immu-
nogenicity but lack of, or modest, protection in human clinical
trials of vaccines (see above) compared to the efficacy of these
vaccines in animals raises thequestionofwhat is immunologically
different about these specific vaccines or the target host. Clearly
size alone is not the sole factor, since theWest Nile DNA vaccine
is effective in horses. Nor is the reason simply that DNA vaccines
somehow work in fish but not in humans (Kurath, 2005). The
effectiveness for the salmon and West Nile vaccine may in part
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Because the IHNV G protein triggers innate immune responses
in addition to the cognate immunity and memory responses
(Purcell et al., 2006), the combination of interferon (Acosta
et al., 2006), (Yasuike et al., 2007), neutralizing antibodies and
T cells (Corbeil et al., 2000), specifically induced by the G protein
may point as much to the antigen and its induction of a diverse
immune responses as to the vaccine modality. For West Nile
virus, the PreM-E antigen when given as a DNA vaccine was
immunogenic and effective against viral challenge in mice and
horses (Davis et al., 2001). A DNA vaccine coding for the
Pre-M and E antigens and core has been shown to generate
neutralizing antibodies and CD4+ and CD8+ T cell responses in
humans (Martin et al., 2007 and ClinicalTrials.gov identifier
NCT00106769).
Any discussion of the immune mechanisms of vector
vaccines, must discuss the use of vectors to not simply generate
de novo immune responses against pathogens, but to bias the
immune response for therapy or prevention of allergies and
autoimmune diseases, as well as to break tolerance against
self antigens for immunotherapy of cancer. For the latter, the
use of DNA encoding human tyrosinase is the basis for the
licensed dog melanoma therapy mentioned above (Liao et al.,
2006). Although these studies raise the specter of autoimmune
diseases, it is interesting that DNA vaccines are specifically
being developed to generate tolerance for therapy of autoim-
mune diseases. The rationale behind such efforts is that through
the use of plasmid DNA encoding a protein such as proinsulin,
tolerance can be induced to the insulin resulting in a lower rate
of diabetes in diabetogenic mice (Solvason et al., 2008). The
effect was due to the generation of Th1 helper responses, with
the production of g-interferon, and could be manipulated by
the protocol of administration of the DNA vaccine as well as
factors such as the amount of, and intracellular location of the
production of the protein. The induction of Th1 cell responses
has also been beneficial in preclinical models of allergies, where
DNA vaccines bias toward a Th1 cell type of response versus the
pro allergenic Th2 cell and IgE antibodies directed against the
allergens (Chua et al., 2009).
Concluding Remarks
The rationales for vaccine vectors are myriad: generation of
specific types of immune responses, including CTLs and partic-
ular types of T cell help, the ability to target antigens to certain
cell types and certain intracellular processing compartments,
the ability to deliver antigens orally to generate mucosal immune
responses (as well as for the ease of delivery), and for harnessing
various antigen-specific and innate immune responses. The
applications range from prophylactic vaccines for infectious
diseases to immunotherapy of cancer, allergies, and autoim-
mune diseases, highlighting the diversity of immunologic mech-
anisms. While the human clinical development of vectored
vaccines has been frustrating with the failure of one HIV vaccine,
and the very modest results of another, the efficacy of animal
vector vaccines, and the insights gained from the preclinical
and clinical studies of vector vaccines point toward the
enormous potential of the vectors for developing vaccines and
immunotherapies as well as for illuminating the incredible
complexities of the immune system.REFERENCES
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